HemoSphere Alta Study
← catalyst calendarNCT07148323 · readout ≤ 103 d
Sponsored by Becton, Dickinson and Company (industry) · BDX — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
100estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-14 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hemodynamic Instability
Intervention
- Device: HemoSphere Alta Monitor, Swan-Ganz IQ pulmonary arterial catheter, ForeSight IQ Large sensor, and Acumen IQ sensor
Primary outcome
what the primary-completion date above is the date OFData Collection using HemoSphere Alta Advanced Monitoring Platform and associated devices
measured Up to 72 hours of device data collection during surgery and ICU
Permalink · BDX's whole pipeline · Catalyst calendar · Every registered study · What changed